News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AmpliPhi Biosciences (TGEN) Signs Global R&D Agreement With US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections



7/1/2013 8:46:07 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

RICHMOND, Va. & SYDNEY & LONDON--(BUSINESS WIRE)--AmpliPhi BioSciences Corporation (OTC:APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced today a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research and Materiel Command (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES